- Home
- JGH vs BMEA Comparison
JGH vs BMEA Comparison
Compare JGH & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- BMEA
- Stock Information
- Founded
- JGH 2014
- BMEA 2017
- Country
- JGH United States
- BMEA United States
- Employees
- JGH N/A
- BMEA N/A
- Industry
- JGH Investment Managers
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- BMEA Health Care
- Exchange
- JGH Nasdaq
- BMEA Nasdaq
- Market Cap
- JGH 295.7M
- BMEA 145.0M
- IPO Year
- JGH N/A
- BMEA 2021
- Fundamental
- Price
- JGH $12.91
- BMEA $3.89
- Analyst Decision
- JGH
- BMEA Buy
- Analyst Count
- JGH 0
- BMEA 13
- Target Price
- JGH N/A
- BMEA $37.25
- AVG Volume (30 Days)
- JGH 73.9K
- BMEA 1.1M
- Earning Date
- JGH 01-01-0001
- BMEA 10-29-2024
- Dividend Yield
- JGH 9.85%
- BMEA N/A
- EPS Growth
- JGH N/A
- BMEA N/A
- EPS
- JGH N/A
- BMEA N/A
- Revenue
- JGH N/A
- BMEA N/A
- Revenue This Year
- JGH N/A
- BMEA N/A
- Revenue Next Year
- JGH N/A
- BMEA N/A
- P/E Ratio
- JGH N/A
- BMEA N/A
- Revenue Growth
- JGH N/A
- BMEA N/A
- 52 Week Low
- JGH $10.36
- BMEA $3.61
- 52 Week High
- JGH $12.85
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- JGH 39.53
- BMEA 26.06
- Support Level
- JGH $12.68
- BMEA $3.74
- Resistance Level
- JGH $12.87
- BMEA $4.30
- Average True Range (ATR)
- JGH 0.13
- BMEA 0.40
- MACD
- JGH -0.02
- BMEA 0.01
- Stochastic Oscillator
- JGH 26.76
- BMEA 6.84
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.